GENErating Behavior Change, An Integrative Health Coaching and Genetic Risk Testing Pilot
GENErating Change, An Integrative Health Coaching and Genetic Risk Testing Pilot in Primary Care: A Multidisciplinary Approach to Personalized Medicine Targeting CHD Risk
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age 18+,
presence of at least one of the following:
- FPG > 100,
- HbA1c > 5.7%,
- diabetic,
- LDL > 129,
- triglycerides > 150,
- total cholesterol > 200,
- SBP > 130,
- BMI > 25,
- able to speak and understand English,
- able and willing to give informed consent
Exclusion Criteria:
- diagnosed CHD (MI or documented coronary artery disease),
- inability to ambulate or participate in physical activity,
- serious chronic disease related complications,
- current participation in a risk communication study for chronic disease,
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Standard Risk Assessment (SRA) Only
|
All 4 arms are assigned to receive standard assessment on coronary heart disease risk
|
|
Experimental: SRA plus Health Coaching
|
All 4 arms are assigned to receive standard assessment on coronary heart disease risk
biweekly health coaching for 5 months
|
|
Experimental: SRA plus Genetic Testing
|
All 4 arms are assigned to receive standard assessment on coronary heart disease risk
Genetic testing results of 9p21
|
|
Experimental: SRA plus Health Coaching plus Genetic Testing
|
All 4 arms are assigned to receive standard assessment on coronary heart disease risk
biweekly health coaching for 5 months
Genetic testing results of 9p21
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diet
Time Frame: 6 months
|
National Cancer Institute (NCI) Multifactor Screener
|
6 months
|
|
Physical Activity
Time Frame: 6 months
|
Stanford Brief Activity Scale (SBAS)
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Fasting blood glucose
Time Frame: 6 months
|
6 months
|
|
Systolic blood pressure
Time Frame: 6 months
|
6 months
|
|
Body mass index
Time Frame: 6 months
|
6 months
|
|
Waist circumference
Time Frame: 6 months
|
6 months
|
|
Low Density Cholesterol (LDL)
Time Frame: 6 months
|
6 months
|
|
Triglyceride
Time Frame: 6 months
|
6 months
|
|
Total cholesterol
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Pro00029973
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Heart Disease Risk
-
NCT01120405CompletedElevated Cardiac Risk | Coronary Arteries Disease Risk
-
NCT00005163CompletedHeart Diseases | Cardiovascular Diseases | Coronary Heart Disease Risk Reduction
-
NCT00005700CompletedHeart Diseases | Cardiovascular Diseases | Coronary Heart Disease Risk Reduction
-
NCT00005529CompletedHeart Diseases | Cardiovascular Diseases | Coronary Heart Disease Risk Reduction
-
NCT00005726CompletedHeart Diseases | Cardiovascular Diseases | Coronary Heart Disease Risk Reduction
-
NCT00005689CompletedHeart Diseases | Cardiovascular Diseases | Coronary Heart Disease Risk Reduction
-
NCT06132568CompletedHeart Disease, Coronary | High-risk Percutaneous Coronary Intervention
-
NCT00005411CompletedHeart Diseases | Cardiovascular Diseases | Coronary Heart Disease Risk Reduction
-
NCT00005746CompletedHeart Diseases | Cardiovascular Diseases | Coronary Disease | Coronary Heart Disease Risk Reduction
-
NCT00685776CompletedCoronary Heart Disease (CHD) | CHD Risk-Equivalent Disease
Clinical Trials on Standard Risk Assessment
-
NCT01884545CompletedPrediabetic State | Coronary Heart Disease, Susceptibility to, 5
-
NCT06507384CompletedRisk Factors | Risk Assessment
-
NCT05834933CompletedBreast Cancer | Health Behavior | Health Knowledge, Attitudes, Practice | Health Care Utilization | Risk Reduction Behavior
-
NCT05893134Completed
-
NCT04196634Active, not recruitingMusculoskeletal Pain Disorder
-
NCT03320239UnknownUsing HIV Risk Assessment Tool to Promote HIV Testing Among Men Who Have Sex With Men (online-RASSL)HIV Infections | HIV/AIDS | Social Media
-
NCT00627159UnknownCardiovascular Diseases | Hypertension | Hyperlipidemia